Minerva Neurosciences, Inc. (NERV): Total Liabilities
$233.76M
As of 2025-12-31
$296.65M
As of 2026-06-30
+46.0%
3-year compound annual growth
+116.1%
5-year compound annual growth
+24.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $233.76M | +272.0% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $62.84M | -26.4% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $85.36M | +13.6% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $75.11M | +8.6% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $69.15M | n/m | 2023-03-08, Balance as of period end |
| 2020-12-31 | $4.96M | -90.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $49.72M | +1.7% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $48.87M | -6.2% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $52.10M | +93.2% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $26.96M | -1.1% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $27.26M | +60.8% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $16.95M | +88.4% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $9.00M | n/a | 2015-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $233.76M | +272.0% |
| iBio, Inc. (IBIO) | 2026-06-30 | $13.40M | +61.3% |
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $56.08M | +46.7% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $7.49M | -27.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $7.16M | +52.5% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $11.04M | +13.9% |
Compare NERV, IBIO, CTOR, ABUS side by side · Screen every company in Pharmaceutical Preparations ↗